기관회원 [로그인]
소속기관에서 받은 아이디, 비밀번호를 입력해 주세요.
개인회원 [로그인]

비회원 구매시 입력하신 핸드폰번호를 입력해 주세요.
본인 인증 후 구매내역을 확인하실 수 있습니다.

회원가입
서지반출
가정의학과 외래 우울증환자에서 moclobemide의 안전성 및 유효성 평가를 위한 시판후조사
[STEP1]서지반출 형식 선택
파일형식
@
서지도구
SNS
기타
[STEP2]서지반출 정보 선택
  • 제목
  • URL
돌아가기
확인
취소
  • 가정의학과 외래 우울증환자에서 moclobemide의 안전성 및 유효성 평가를 위한 시판후조사
저자명
김영식,이근미,김병성,신호철,성은주,이상엽,문유선,송상욱,김철환,선우성,Kim. Young-Sik,Lee. Keun-Mi,Kim. Byung-Sung,Shin. Ho-Cheol,Sung. Eun-Ju,Lee. Sang-Yeoup,
간행물명
臨床藥理學會誌= The journal of Korean Society for Clinical Pharmacology and Therapeutics
권/호정보
2002년|10권 1호|pp.51-61 (11 pages)
발행정보
대한임상약리학회
파일정보
정기간행물|
PDF텍스트
주제분야
기타
이 논문은 한국과학기술정보연구원과 논문 연계를 통해 무료로 제공되는 원문입니다.
서지반출

기타언어초록

Background : Depression is quite a common disease in primary care however, studies for the safety and effectiveness of antidepressants in primary care setting are rare in Korea. Objectives : This multi-centered post-marketing study was performed to evaluate the safety and effectiveness of Moclobemide and to find out the factors related to the adherence among patients with depression in family practice. Methods : A total of 386 patients were enrolled from July 1999 to January 2000 by twenty family doctors from fifteen family practice centers. They were prescribed Moclobemide and were reevaluated at the 4th, 8th, and l2th week. Evaluation of compliance, safety and effectiveness were performed with pre-made, structured self-reported questionnaires. Evaluation of effectiveness was also performed utilizing self-rating depression scale (SDS). Results : Among 386 patients, safety was evaluated in 310 patients and effectiveness was evaluated in 239 patients. During the first 12 weeks, the number of subjects continuing with Mocclobemide was 136(37.1%). 141 subjects (38.4%) discontinued taking the drug and 90 subjects (24.5%) dropped out at the 12th week. Considering drop-out patients as ineffective cases, overall effectiveness was estimated to be 84.5%. Symptoms improved with time in patients whose follow-up were completed (P<0.01). The SDS score decreased by an average of ${6.8{pm}9.1(12.2{pm}19.1%)}$ after 12 weeks(p<0.01). During the study, 33(10.6%) subjects reported adverse events. The most commonly reported adverse events, in descending order, were dizziness(2.3%), headache(1.6%), insomnia(1.3%), facial edema(1.3%), constipation(1.0%), nausea(1.0%) and tremor(1.0%). The main reasons for discontinuing antidepressants were attributed to improvement of symptoms and manifestation of adverse events. Conclusion : The percentage of adherence at 12th week of Moclobemire among patients suffering from depression in the family practice outpatient clinic was shown to be 49%. The antidepressant effect and safety of Moclobemide was relatively superior.